Novo Nordisk pushes insurers as weight-loss drug demand soars
#Wegovy #InsuranceCoverageNovo Nordisk pushes insurers to cover Wegovy costs, seeking balance with direct sales. Demand soars for obesity drugs despite employer pushback. Medicare pilot launching in July offers $50 monthly access, aiming to solve cost trend concerns. read more
Insurance Denies Weight Loss Drugs? Here’s How to Fight Back
#GLP1 #InsuranceCoverageIf your insurance denies GLP-1 weight loss drugs, check fine print for qualifying conditions like sleep apnea. File appeals with doctor support, document care meticulously, seek discounts, and consider compounded options cautiously. Persistence is key. read more
Insurance Cuts Off Weight-Loss Drugs, Patients Scramble
#ObesityDrugs #InsuranceCoverageInsurance coverage for GLP-1 obesity drugs like Wegovy and Zepbound is declining, forcing patients to pay high out-of-pocket costs or switch medications. Many face restrictive policies, leaving them to navigate financial and medical uncertainty alone. read more